Central venous catheters and complications
Keywords:
implantable venous ports, complication, prevention, treatmentAbstract
Permanent venous line access is of a great importance in the treatment of oncological patients who are undergoing long-term chemotherapy. Modern medicine could not exist without a regular and reliable venous line access. In many departments central venous line (venous port systems), which allows a patient to move freely without fear of accidental removal of a catheter are used routinely. Venous port system consists of a reservoir compartment with a silicone membrane - septum, which can be repeatedly punctured, and a thin-walled intravascular catheter. A port is an undeniable convenience for patients and can fulfill its role for many months or even years. Especially in oncology the need to ensure permanent vascular line access is an essential part of the therapy due to severe irritation caused by many cytostatics. The aim of this study is to present the current standards and guidelines concerning intravenous port system and the most common early and late complications caused by the presence of central venous catheter. Based on a review of the bibliographical data, the authors presented the risk of common complications of central venous cannulation, the mechanism and the factors influencing the complications associated with the use of venous ports. Complications are an integral part of any medical treatment, therefore it is essential to understand their mechanism and learn appropriate methods of treatment and prevention. The use of ports is becoming increasingly popular in Polish oncology. Therefore, physicians should be familiar with advantages and common complications of the use of venous ports. Most of the complications result from the failure to comply with procedures, lack of adequate supervision, negligence or simply insufficient knowledge.
Downloads
References
Młynarski R. Port dożylny. Wydawnictwo Info Studio s.c . Lublin 2009.
Dudrick SJ (tłum.Pertkiewicz M). Historia dostępu naczyniowego. Postępy Żywienia Klinicznego 2006;1:6-14.
Jarosz J. Kaniulacja żył centralnych w celu podawania chemioterapii w onkologii. W: Krzakowski M. (red.). Onkologia Kliniczna. Wydawnictwo Medyczne Borgis, Warszawa 2001; 485– 498.
Kurul S, Saip P, Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. The Lancet Oncol 2002; 3(11): 684–692.
Rupp SM, Apfelbaum JL, Blitt C, et al. Practice Guidelines for Central Venous Access. A Report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology 2012;116:539-573.
Jarosz J, Krzakowski M, Dworzański K, i wsp. Wszczepialne systemy dostępu naczyniowego o długotrwałym zastosowaniu („porty''). Onkologia w Praktyce Klinicznej 2006;2:40-49.
Jarosz J, Misiak M, Góraj E, Kruczyk K, Wikłacz R. Wszczepialne systemy dostępu naczyniowego do podawania chemioterapii („porty dożylne''). W: Krzakowski M. i wsp. (red.). Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych .Via Medica, Gdańsk 2011;1:573- 576.
Barbetakis M, Asteriou C, Kleontas A, Tsilikas C. Totally implantable central venosus access ports. Analysis of 700 cases . J Surg Oncol. 2011;104(6):654-656.
Jastrzębska M.(red.). Diagnostyka laboratoryjna w hemostazie. Wydawnictwo Ośrodek Informacji Naukowej Oinpharma , Warszawa 2009.
Troianos CA, Hartman GS , Glas KE ,et al. Guidelines for Performing Ultrasound Guided Vascular Cannulation :Recommendations of the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr. 2011;24:1291-1318.
Vezzani A, Brusasco C, Palermo S, Launo C, Mergoni M, Corradi F. Ultrasound localization of central vein catheter and detection of postprocedural pneumothorax: an alternative to chest radiography. Crit Care Med 2010;38:533-538.
Jordan K, Behlendorf T, Surov A, Kegel T, Maher G, Wolf HH. Venous access ports: frequency and management of complications in oncology patients. Oncology 2008;31(7):404–410.
Rosen M, Latto IP, Shang Ng. W: Kaniulacja żył centralnych. Alfa Medica press, Bielsko- Biała 1999.
Młynarski R. Porty dożylne u pacjentów onkologicznych. Analiza sześciu lat stosowania portów dożylnych w Centrum Onkologii Ziemi Lubelskiej. Onkologia i Radioterapia 2008;4:22-29.
Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW. Implantable vascular acces systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 1998;22:12-6.
Yildizeli B, Lacin T, Batirel HF , Yüksel M. Complications and management of long-term central venosus acces catheters and ports. J Vasc Acces 2004;5:174-8.
Schiffer ChA, Mangu P , Wade JC. et al. Central Venous Catheter Care for the patient with Cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 2013;31:1357-1370.
Bagnall-Reeb H. Evidence for the use of the antibiotic lock technique. J Infus Nurs 2004; 27:118–122.
Kahn SR., Lim W., Dunn AS. et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence –Based Clinical practice Guidelines. CHEST 2012 ;141(2 suppl):e195S-e226S.
Glaser DW, Medeiros D, Rollins N, Buchanan GR. Catheter-related thrombosis in children with cancer. J Pediatr. 2001;138:255–259.
Akl EA, Rohilla S, Barba M. et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: A systematic review. Cancer 2008;113:1685–1694.
Linenberger ML. Catheter-related thrombosis: Risks, diagnosis, and management. J Natl Compr Canc Netw 2006;4:889–901.
Masci G, Magagnoli M, Zucali PA et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003;21:736–739.
De Cicco M, Matovic M, Balestreri L, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: A randomized controlled study based on serial venographies. Ann Oncol 2009;20:1936–1942.
Young AM, Billingham LJ, Begum G, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): An open-label randomised trial. Lancet 2009;373:567– 574.
Horne MK , McCloskey DJ, Calis K, Wesley R, Childs R, Kasten-Sportes C. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices. Pharmacotherapy 2006;26:1262–1267.
Niers TM, Di Nisio M, Klerk CP, Baarslag HJ, Büller HR, Biemond BJ . Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007;5 (9): 1878-1882.
Karthaus M, Kretzschmar A, Kröning H et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: Final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289–296.
Ruud E, Holmstrm H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line- associated thromboses in children with malignancies: A randomized, controlled study. Acta Pediatr 2006; 95:1053–1059.
Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063–4069.
Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057–4062.
Abdelkefi A, Ben Othman T, Kammoun L, et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease: A randomized controlled trial. Thromb Haemost 2004;92:654– 661.
Chaukiyal P, Nautiyal A Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters: A systematic review and meta-analysis. Thromb Haemost 2008;99:38–
Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters: A reappraisal of the evidence. Br J Cancer 2006; 94:189– 194.
Chan A, Iannucci A, Dager WE. Systemic anticoagulant prophylaxis for central catheter- associated venous thrombosis in cancer patients. Ann Pharmacother 2007;41:635–641.
Akl EA, Karmath G, Yosuico V, et al. (2007) Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database Syst Rev 2007; 18: CD006468.
Rawson KM, Newburn-Cook CV. The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: A meta-analysis. Oncol Nurs Forum 2007; 34:1037–1043.
Omidi M, Ławiński M, Pertkiewicz M. Późne przemieszczenie końca cewnika Broviaca do żyły szyjnej wewnętrznej po napadzie kaszlu. Postępy Żywienia Klinicznego 2006;1;36
Mączyńska B, Przondo-Mordarska A . Zakażenia krwi związane z zastosowaniem dostępu naczyniowego . Zakażenia 2011;4:107-116
Mączyńska B, Smutnicka D, Przondo-Mordarska A, et al. Biofilm formation by clinical Klebsiella strains expressing various types of adhesins on chemically different catheters, Adv Clin Exp Med 2010;19: 443–453.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
